Regulation· Brief · October 10, 2026, 4:02 AM ET

FDA finalizes guidance on post-approval manufacturing changes to biosimilars

FDA announced the availability of a final guidance titled "Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Questions and Answers." The guidance supersedes the draft issued July 23 2024 and withdraws Q&A I.20 from the Q&A biosimilar development guidance.

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation